ArticleCancer management and research2021
Comprehensive Analysis of the Prognostic Value and Immune Infiltrates of the Three-m5C Signature in Colon Carcinoma.
Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 20 citations in OpenAlex.
- Exploring MFSD9: From Expression Patterns to Therapeutic Implications in LUAD.Current medicinal chemistry · 2026Article
- m5C-Related Regulators Define Tumor Microenvironment and Predict Prognosis in Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Detection, molecular function and mechanisms of m5C in cancer.Clinical and translational medicine · 2025Review
- RNA modifications in cancer.MedComm · 2025Review
- RNA m5C modification: from physiology to pathology and its biological significance.Frontiers in immunology · 2025Review
- RNA 5-Methylcytosine Modification: Regulatory Molecules, Biological Functions, and Human Diseases.Genomics, proteomics & bioinformatics · 2024Review
- Review
- Prognostic signature and immune landscape of 5-methylcytosine-related long non-coding RNAs in gastric cancer.Heliyon · 2024Article
- Molecular features, biological behaviors and clinical implications of mCancer biology & therapy · 2023Article
- Vital roles of mFrontiers in immunology · 2023Review
- Contribution of m5C RNA Modification-Related Genes to Prognosis and Immunotherapy Prediction in Patients with Ovarian Cancer.Mediators of inflammation · 2023Article
- Role of main RNA modifications in cancer: NSignal transduction and targeted therapy · 2022Review
- Biological roles of RNA mBiomarker research · 2022Review
- Diagnostic and prognostic value of m5C regulatory genes in hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Analysis of the Prognostic Significance and Immune Infiltration of the Amino Acid Metabolism-Related Genes in Colon Adenocarcinoma.Frontiers in genetics · 2022Article
- The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma.BioMed research international · 2022Article
- Development and Validation of an 8-Gene Signature to Improve Survival Prediction of Colorectal Cancer.Frontiers in oncology · 2022Article
- Comprehensive Analysis of 5-Methylcytosine (mFrontiers in oncology · 2022Article
- 5-Methylcytosine (mFrontiers in immunology · 2022Article
- Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma.Frontiers in cell and developmental biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 5-methylcytosine (m5C) is one of the important forms of RNA post modification, and its regulatory mechanism in tumors has received increasing attention. However, its potential role in colorectal cancer remains unclear. MATERIALS AND
methodsHere, we systematically investigated the genetic variation and prognostic value of the 14 m5c RNA methylation regulators in colon cancer. The prognostic risk score was constructed using three m5C regulators, which was verified in the GSE17536 (N=177), GSE41258 (N=248) and GSE38832 (N=122) datasets.
resultsThe risk score developed from the three-m5C signature represents an independent prognostic factor, which can accurately predict the prognosis of patients with colon cancer in multiple datasets. The cytokine-cytokine receptor interaction and chemokine signaling pathway were significantly enriched in the low-risk score group. Further analysis showed that the three-m5C signature was related to tumor immune microenvironment (TIME), affecting the abundance of tumor-infiltrating immune cells. Especially, patients with low risk score had higher immune score than those with high risk score. In addition, gene set enrichment analysis (GSEA) confirmed that all three regulatory factors are associated with the MAPK/p38 signaling pathway.
conclusionIn conclusion, our study illustrates that the three-m5C signature may be involved in the regulation of colon cancer immune microenvironment in synergy with the MAPK signaling pathway. Therefore, further studying the three-m5C signature regulatory mechanisms might provide promising targets for improving the responsiveness of colon cancer to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.